The Scrutiny on Rebates and Prices Will Change the Pharma-Payer Relationship

As the largest payer in the US, the government is understandably concerned about the high price of drugs. How will the rebate debate end? In this PM360 article, Precision for Value VP Andy Cournoyer describes a stumbling block—administrative fees—and posits some solutions.

Read the article

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.